Our portfolio

Novel antibodies for leading cause of neonatal sepsis

Arsanis focuses on the discovery and development of novel monoclonal antibodies (mAbs) to prevent and treat infectious disease. The foundation is working with Arsanis to develop a prophylactic mAb candidate targeting Stap aureus, a leading cause of neonatal sepsis that leads to around 345,000 annual deaths globally.
Website
  • Domain
    Life Sciences
  • Investment type
    Direct equity
  • Status
    Exit
  • Initial investment
    Series D
  • Partnered in
    2017
  • Headquarters
    USA
  • Program strategy
    Discovery & Translational Sciences

More about our work

Our focus

Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.

Investment approach

Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.

Our team

We bring depth of experience to every investment, with a proven track record across sectors and scale.